Predict your next investment

HEALTHCARE | Drug Development

See what CB Insights has to offer

Founded Year

1986

Stage

IPO | IPO

Total Raised

$41.4M

Date of IPO

6/5/1990

About SICOR

Developer of therapeutic drugs based on research in purine/pyrimidine metabolism for treatment of cardiovascular, cerebrovascular, neurological and inflammatory diseases. Also research and development in catecholamine analogues. The first product from this program combines a novel drug with a proprietary, computer-controlled, non-invasive delivery system to enhance the diagnosis, prognosis and management of cardiovascular disease significantly. As of January 1990, there are two drugs in phase II clinical trials in Europe. They are ARA (adenosine regulating agent) and ESA (exercise stimulating agent). The IND for ARA has been filed with the FDA. Company anticipates that both drugs will be available in Europe by mid-1993 and in the United States by mid-1994.

SICOR Headquarter Location

11075 Roselle Street

San Diego, California, 92121,

United States

(619)546-8300

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

SICOR Patents

SICOR has filed 22 patents.

The 3 most popular patent topics include:

  • Amino acids
  • Dicarboxylic acids
  • Experimental cancer drugs
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/23/2016

8/1/2017

Experimental cancer drugs, Dicarboxylic acids, Monoclonal antibodies, Amino acids, Monoclonal antibodies for tumors

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

11/23/2016

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

8/1/2017

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Experimental cancer drugs, Dicarboxylic acids, Monoclonal antibodies, Amino acids, Monoclonal antibodies for tumors

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.